Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2021-05-19 Regulatory Filings
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics Announces the Publication of New Scientific Article in Biomedecine et Pharmacotherapy which further strengthen its Phase III development plan in difficult to treat and resistant hyper
Regulatory Filings Classification · 90% confidence The document is a press release from Quantum Genomics announcing the publication of a new scientific article in a peer-reviewed journal (*Biomedecine & Pharmacotherapy*) regarding the efficacy of their drug candidate, firibastat. This announcement details scientific findings relevant to their ongoing clinical trials (Phase III development plan). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a management discussion (MDA). It is an announcement of scientific/research progress. Since there is no specific category for 'Scientific Publication Announcement' and it is not a general regulatory filing (RNS) or an investor presentation (IP), it best fits under the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-financial, non-governance announcement, or potentially 'LTR' if the publication is viewed as a report on legal/regulatory progress, but RNS is the most appropriate fallback for general corporate news releases that don't fit elsewhere. Given the context of scientific progress updates, RNS is the best fit among the provided options for a general corporate announcement not covered by other specific codes.
2021-05-19 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it provides 'Information relative au nombre total de droits de vote et d'actions composant le capital' (Information relative to the total number of voting rights and shares comprising the capital) as of a specific date (01/04/2021), referencing French commercial code (Article L. 233-8-II du Code de commerce) and AMF regulations. This type of filing, detailing the total share count and voting rights, is a mandatory periodic disclosure in many jurisdictions. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit for a formal announcement detailing the total number of voting rights and shares, even if it's not the result of a specific vote, but rather a periodic update on the capital structure for voting purposes. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV).
2021-05-18 French
Quantum Genomics Secures 3 Million euros Non-dilutive Financing
Capital/Financing Update Classification · 99% confidence The document is a press release announcing that Quantum Genomics has secured €3 million in non-dilutive financing through a government-guaranteed loan (PGE) and an R&D loan from Bpifrance. The core subject is the acquisition of new funding and capital structure changes, specifically loans rather than equity issuance or share buybacks. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER) as it focuses on financing, not operational results, nor is it a full Annual Report (10-K) or Interim Report (IR).
2021-04-28 English
Obtention de financements non-dilutifs de 3 millions d'euros
Capital/Financing Update Classification · 99% confidence The document explicitly announces the 'Obtention de financements non-dilutifs de 3 millions d'euros' (Obtaining non-dilutive financing of 3 million euros), detailing two specific loans (PGE and Innovation R&D loan) from BNP and BPIfrance. This content directly relates to fundraising, financing activities, and changes in capital structure. Based on the definitions, this aligns perfectly with the 'Capital/Financing Update' category (Code: CAP). The document length is relatively short (2889 chars), but it is the primary announcement of the financing event itself, not just an announcement that a report is attached, thus ruling out RPA/RNS.
2021-04-28 French
2020 annual report
Annual Report Classification · 100% confidence The document is explicitly titled '2020 ANNUAL REPORT' and covers the fiscal year ended 31 December 2020. It contains comprehensive sections including a message from the CEO, company activity, management report, detailed financial statements, and statutory auditor reports. This aligns perfectly with the definition of an Annual Report (10-K). FY 2020
2021-04-27 English
Quantum Genomics will Present Top-line Results from its QUORUM study of Firibastat in Heart Failure post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Quantum Genomics will present top-line results from its QUORUM study at the European Society of Cardiology (ESC) Meeting in August 2021. It details the study design, endpoints, and provides quotes from the CEO and lead investigator. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal dividend/share change notice. It is an announcement about upcoming scientific/clinical data presentation, which often falls under general investor relations or regulatory announcements. Since it is a specific announcement about clinical trial results being presented at a major medical conference, and it is not a formal financial filing, it best fits the general 'Regulatory Filings' (RNS) category as a significant corporate update, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the options, RNS serves as the best catch-all for significant, non-standard regulatory/corporate news releases that aren't explicitly covered by other codes like ER or DIV. The document length (4227 chars) is short enough that if it were just announcing an attached report, it would be RPA, but here it contains substantial content about the study itself, making it a substantive announcement.
2021-04-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.